Austar Lifesciences' low P/S ratio may be a buying opportunity, but its poor financial performance and declining revenue are concerning. Despite higher medium-term revenue growth rates than the industry average, the continued decline in stock price and P/S ratio indicates potential risks.
Investors fear the company may underperform the broader industry soon, despite strong revenue growth. Shareholders think recent performance has peaked, accepting lower selling prices. Underlying risks to profitability are pressuring the P/S ratio.
$奧星生命科技(06118.HK)$really die die must trade this conman stock, remember core principle parabolic price movement is a caution indicator, impulsive wave up will follow by impulsive wave down, if price move like a staircase then no need to worry.
2
1
報告
70740049 :
if analyse chart, will rebound? what price?
$奧星生命科技(06118.HK)$I remember this stock was push to 30 dollars, if investors are lucky to have bought at the peak and currently selloff to 8 might see a support at 6 for rebound if not another level will be 3 dollars.
奧星生命科技に関するコメント
まだコメントはありません